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hromboembolic
omplications After
urgical Correction
f Mitral Regurgitation
inding a Balance*
obert A. Dion, MD, PHD
enk, Leuven, Belgium
n this issue of the Journal, Russo et al. (1) report on
hromboembolic complications after surgical correction of
itral regurgitation (MR). The authors present a retrospec-
ive analysis of the risk of thromboembolic and hemorrhagic
omplications in 1,344 patients operated on for pure MR
etween January 1980 and December 1995. They have
chieved a remarkably complete follow-up (98.2%) and have
bserved the timing of these complications in 3 phases: up
o 30 days, between 30 and 180 days, and from 180 days to
0 years. They have also compared the results between
itral valve repair (Mrep) (n  897), mitral valve replace-
ent with a bioprosthesis (MVRb) (n  216), and mitral
alve replacement with a mechanical valve (MVRm) (n 
31). Concomitant CABG was accepted in the inclusion
riteria and was evenly distributed over the different groups.
See page 1203
f more concern is the inclusion of 76 endocarditis cases,
hich by themselves might have exerted a significant influence
n the thromboembolic events. Another and greater concern
s the conduct of anticoagulation beyond discharge: “the
ubsequent intensity and duration of anticoagulation was
etermined by patients’ physicians. . .” We know how much
nticoagulation regimens can vary among physicians with-
ut speaking of the inconstant discipline of the patients
hemselves. On the other hand, the authors might answer
hat the results presented illustrate anticoagulation in the
eal life of a large population of patients.
Obvious differences existed in the baseline pre-operative
haracteristics of the patients undergoing the 3 types of
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.s
From the Department of Cardiac Surgery, ZOL-Campus St-Jan, Genk, Leuven,
elgium.rocedures, including age, the percentage with organic MR,
nd the percentage with atrial fibrillation (AF). Therefore,
he authors compared the incidence of stroke after these
rocedures with the expected incidence of stroke in an
lmsted County population with similar characteristics.
As mentioned by the authors, the general results bring
ood news and bad news. The good news is that the excess
isk of stroke and thromboembolic complications disappears
eyond 6 months after MRep and MVRb. The bad news is
hat the incidence of stroke is approximately 40 higher than
n the control population during the first 30 post-operative
ays and was independent of the procedure. Between 1 and 6
onths after the operation, the excess risk of stroke was
ariable: 2.1 for MRep, 1.5 for MVRb, and 10.4 for MVRm.
he authors found that systemic hypertension, age, and
VRmwere independent predictors of ischemic stroke during
ntermediate follow-up, and age andMVRm also at long-term
ollow-up, which is not unexpected. The observation that AF
as not an independent predictor was a great surprise.
owever, the influence of AF is masked by the MVRm
roup. After exclusion of these patients, AF becomes a
efinite independent predictor of stroke. This is an impor-
ant issue because no less than 544 patients (41%) had
re-operative chronic AF and 168 patients (12.5%) devel-
ped AF during the follow-up period. Besides, we know
hat brief or paroxysmal AF occurs in the early post-
perative course in up to 25% of patients. However, the
edical, interventional, and surgical treatments of AF have
pectacularly evolved since 1995, which is not taken into
ccount here. Nowadays, in experienced centers, concomi-
ant AF is addressed by ablation lines in both atria and
xclusion of the left appendage, particularly after MRep or
VRb, with a maximum success rate of 80% to 90% at
ollow-up.
One of the Russo et al. (1) most definite conclusions is
hat “MVRm is the least desirable mode of correction of
R.” The long-term risk of ischemic stroke was 3 higher
nd the risk of bleeding 2.5 higher than in MVRb. Also
he linearized rate of “all embolic events” is much higher in
VRm than in MVRb (4.3 vs. 2.8 per 100 patient-years).
he authors nearly conclude that MVRm should be banned
rom the surgical armamentarium. I do not share this extreme
ttitude, and the comparison of outcome between mechanical
nd biologic prosthesis in the literature, even in aortic
osition and in the elderly, surprisingly does not lead to
verwhelming evidence of the superiority of MVRb. The
nfluence of thromboembolic and hemorrhagic events needs
o be balanced against the degeneration of the bioprosthesis,
nd the incidence of bioprosthetic degeneration seems
igher in the mitral position than in the aortic position. In
ddition, up to 30% of patients with a bioprosthetic valve
eceive anticoagulation for various reasons, which, according
o the data of the authors, yields a risk ratio of 1.52. If the
alve cannot be preserved, the type of prosthetic device
hould still be adapted case by case, taking into account the
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March 25, 2008:1212–3 Editorial Commentaseline characteristics, quality of the social life, life expect-
ncy, use of anticoagulation, and, last but not least, the
reference of the patient and the findings of this study.
Another of the Russo et al. (1) major conclusions consists
f a warm plea for MRep, “which results in long-term
estoration, not only of life expectancy but also of the
schemic stroke risk.” Mitral valve repair has even been
ound by the authors to be a negative independent predictive
actor for ischemic stroke in the long term (risk ratio 0.5). It
lso provides the lowest long-term risk of bleeding and
mbolic events so that “it is unique in combining long-term
orbidity to mortality benefit” (1). Here, despite the fact
hat the rate of MRep in our center amounts to 90% of all
itral valve surgery, I wish to introduce some nuances about
his statement. At the latest meeting of the American
ssociation for Thoracic Surgery in Washington, DC, the
leveland Clinic colleagues presented an abstract entitled:
Is Survival Always Better After Valve Repair Than After
alve Replacement for Degenerative Mitral Valve Disease?”
heir conclusion was that “in a subset of older, sicker
atients with advanced heart disease, we were unable to
dentify a survival advantage of mitral repair versus replace-
ent.” The official discussant of this paper was Dr. Tirone
avid, one of the most experienced surgeons in MRep. He
rst admitted to having been shocked by the conclusions,
ut after analyzing his own results in this extreme end of the
pectrum, he too became doubtful that there was a definite
dvantage of MRep. Another element is the durability of the
epair in difficult cases. Willem Flameng first reported in
irculation in 2003 (2), and then again at the American
ssociation for Thoracic Surgery meeting in Washington,
C, a linearized rate of recurrent MR class II of 2.8% in the
arlow disease. Some other centers might claim better results,
ut there certainly is an attrition rate after MRep. This
ndividual attrition rate should be ideally defined for each
enter that wants to be a reference for MRep, especially those
enters contemplating treating the asymptomatic patient.
The indications for surgical repair of severe MR in an
symptomatic patient is currently a hot but controversial
opic in the literature. It is well known that one should try
o operate before the onset of AF and before the dilation ofhe left ventricle, but there is also the issue of the above-
entioned attrition rate and the fact that the risk for
schemic stroke is multiplied by 1.6 for the entire follow-up
eriod and by as much as 31 during the first 30 days after
he operation. In reality, it is only a real incidence of 1.5%,
ut it has to be taken into account. We do not really know
he exact risk of ischemic stroke in the setting of asymp-
omatic patients, because the authors have calculated an
verall risk for all of the patients with pure MR. It might
ell be that, in patients who are asymptomatic and therefore
ormally active, the risk of stroke would be less during the
mmediate post-operative course and at follow-up. It would
e interesting to ask the authors of this study to recalculate
he risk of ischemic stroke for patients who have a severe
R and are asymptomatic.
Finally, the authors consider the role of preventive anti-
oagulation in every patient after MRep or MVRb for the
rst 6 months to cover the increased risk of ischemic stroke.
his is a quite difficult issue. There must be a balance
etween the risk of bleeding—which is multiplied by 1.52
fter anticoagulation in this series—and the risk of ischemic
troke or peripheral embolic disease. I believe that only a
rospective randomized trial with very specific guidelines for
nticoagulation will bring the answers.
Nevertheless, this study is essential in demonstrating the
xcess risk incurred by patients undergoing MR surgery for
ertain post-operative phases and procedures and thus helps
efine candidates for future clinical trials.
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